AUTHOR=Avedova Asmik , Deripapa Elena , Rodina Yulia , Mukhina Anna , Latysheva Elena , Yukhacheva Daria , Burlakov Vasily , Kan Nellie , Bogdanova Daria , Moiseeva Anna , Kuzmenko Natalia , Nesterenko Zoya , Deordieva Ekaterina , Ogneva Anna , Bludova Victoria , Roppelt Anna , Fomina Daria , Zinovieva Natalia , Sevostyanova Yulia , Kalmeteva Linara , Prolygina Dilara , Barycheva Lyudmila , Selezneva Olga , Shakhova Natalya , Laba Olga , Vlasova Elena , Gorenkova Alla , Timofeeva Elena , Trusova Olga , Guseva Marina , Yudina Natalya , Grevtseva Evgeniya , Ibisheva Asya , Bambaeva Zema , Mashkovskaya Dina , Isakova Svetlana , Shakirova Almazia , Selina Ekaterina , Shilova Tatyana , Zubova Elena , Khabaeva Iman , Kitova Ekaterina , Mandzhieva Anastasia , Starikova Svetlana , Pavlova Tatyana , Tyulyakova Elvira , Levin Pavel , Grachev Nikolay , Shcherbina Anna 

TITLE=Рrospective multicenter study of treatment efficacy, safety, and quality of life in a large cohort of patients with inborn errors of immunity receiving subcutaneous immunoglobulin by the rapid push method

JOURNAL=Frontiers in Immunology

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1598491

DOI=10.3389/fimmu.2025.1598491

ISSN=1664-3224

ABSTRACT=Subcutaneous immunoglobulin (SCIG) preparations are widely used in patients with inborn errors of immunity (IEI), with proven efficacy and good tolerance. We assessed treatment efficacy, safety, and quality of life in a large cohort of IEI patients who switched from intravenous immunoglobulin (IVIG) to SCIG. Our observational study included 200 patients aged 1–65 years with IEI. SCIG Cutaquig (16.5%) was administered every 7–10 days for at least 12 months via the rapid push method. We assessed the rate of infection, immunoglobulin G (IgG) concentration, adverse events, and quality of life. A total of 8,787 SCIG doses were administered during the study. The rate of infections (per person/month) during SCIG treatment was 0.05, which was significantly lower compared to 0.19 during the IVIG period (p<0.001). The median trough IgG was 6.9 g/L on IVIG, compared to 9.0 g/L during the first six months, and 9.2 g/L during the next six months on SCIG. Systemic reactions occurred in 12.4% of the IVIG infusions and 1.9% of the SCIG infusions. The total scores on quality of life summary assessments of physical and mental health were higher on SCIG therapy compared with IVIG (p<0.001). At the end of the study, 85.6% of the patients chose to remain on SCIG. Our data suggest that SCIG infusion via the rapid push method is effective, well tolerated, and feasible in large groups of IEI patients, including those in large countries such as Russia.